Phase I/II Studies of Azacitidine Alone or with Pracinostat for Patients with AML


Phase I/II Studies of Azacitidine Alone or with Pracinostat for Patients with AML
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Garcia-Manero G et al. Final results from a Phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML). Proc ASH 2015;Abstract 453.

Savona MR et al. CC-486 (oral azacitidine) monotherapy in patients with acute myeloid leukemia (AML). Proc ASH 2015;Abstract 452.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.